

New Horizons GIST – Special Topic:

Mutational Analysis in GIST as a guide for the right therapy...

May 7, 2021, 2-4pm CEST / 8-10am EDST/NYC time

Session 1 (30 Min.): Introduction or repetition: Key Notes
Mutations and Mutational Analysis in GIST

GIST-Pathologist: tbd, USA tbc (15 Min.)

- What is the role of a pathologist in the interdisciplinary GIST team?
- How do GISTs arise genetically / biologically?
- What types of mutations are there in GIST?
- Closer look on mutations in KIT/PDGFR α ?
- What is the difference between primary and secondary mutations?
- Does the mutation have an impact on the course of the disease / prognosis?

GIST-Pathologist: Eva Wardelmann, GER – confirmed (15 Min.)

- In simple steps: How does such a mutational analysis work?
- Costs, time and efforts of mutational analysis?
- What role does/can liquid biopsy play in GIST?
Is this a scientific procedure or clinical practice?
- What do we know about rare mutations -
not localized in KIT or PDGFR α ?
- What are the three most burning (scientific) questions
in GIST from the perspective of a researching pathologist?

Session 2 (30 Min.): Introduction or repetition: Key Notes
Impact of mutations in clinical practice

GIST-Expert/-Oncologist: Rashmi Chugh, USA – confirmed (15 Min.)

The influence of the mutation result on the choice of therapy

- In which cases do primary mutations guide the choice of therapy?
- What role do secondary mutations play in therapy decision?
- What about treatment option for specific, very rare mutations,
such as BRAF, SDH- or NTRK?

GIST-Expert/-Oncologist: Peter Reichardt, GER - confirmed (15 Min.)

Patient cases with rare mutations in which the quality
of therapy management has made a clear difference?

Session 3: (30 Min.): Experiences with mutational testing in GIST:
Short stopovers on a trip around the world?

Patient Representatives from

USA, Canada, Latin America, Chile, The Netherlands, Germany, UK, India (3 – 4 Min. each)

- To what extent is mutational testing available/performed?
- Are costs an issue? How high are the costs and who is covering them?
- Are there misconceptions and wrong information about mutational testing?
- Advocacy activities to raise awareness for mutational testing?

Session 4 (30 Min.) Open questions to the experts and panel-/online-discussion:
How can patient groups, GIST Experts and companies work
better together >>> to establish mutation analysis even better?

GIST-Pathologists, GIST-Experts/-Oncologist, Patient Representatives